Form 4: Astera Labs General Counsel Sells Shares Via 10b5-1 Plan

Astera Labs' General Counsel and Secretary, Philip Mazzara, sold 9,900 shares of common stock on January 2, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Philip Mazzara, General Counsel and Secretary of Astera Labs, Inc. (ALAB), reported transactions on January 2, 2026.
• Mazzara disposed of a total of 9,900 shares of Astera Labs common stock.
• The sales were executed at weighted average prices ranging from $172.65 to $182.12 per share.
• These transactions were conducted automatically pursuant to a Rule 10b5-1 trading plan adopted by Mazzara on May 29, 2025.
• Following these reported transactions, Mazzara beneficially owns 137,040 shares of Astera Labs common stock directly.

Sentiment

Score: 5

Explanation: The sale of shares by an insider, while reducing their direct stake, was conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned liquidity event rather than a reaction to new company-specific information. This makes the sentiment neutral.

Negatives

• The sale of 9,900 shares by a key executive reduces the total insider ownership in the company.

Risks

• While executed under a pre-arranged plan, insider selling can sometimes be perceived negatively by investors, potentially leading to questions about management's long-term confidence in the company's stock performance.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The reduction in insider ownership, though pre-planned, might be noted by investors. However, the pre-scheduled nature of the 10b5-1 plan typically mitigates concerns about immediate negative implications.

Key Dates

Recommendation

The insider sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled liquidity event rather than a reaction to new material information. Without additional context on company performance or market conditions, this transaction alone does not warrant a change from a 'hold' position.

Keywords

Astera Labs, ALAB, insider trading, Form 4, stock sale, Philip Mazzara, 10b5-1 plan, General Counsel, Secretary